Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fecal microbiota, live
- Development stage
- Unknown
- Lead developer
- University of Texas Health Science Center at Houston
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Rectal, Oral
01
Overview
An investigational frozen or lyophilized (freeze-dried) fecal microbiota preparation developed by The University of Texas Health Science Center at Houston (UTHealth) in collaboration with the Kelsey Research Foundation. [2, 4] This biologic therapy is designed to treat recurrent Clostridioides difficile infection (rCDI) by restoring a healthy gut microbiome. [4, 5] The active ingredient consists of diverse bacterial communities derived from the fecal matter of screened healthy donors. [4, 9] In clinical trials, the frozen formulation demonstrated an 83% cure rate for rCDI. [4] Administration is via retention enema or oral capsules. [8]
- Brand names
- RebyotaBIOMICTRA
- Other names
- frozen microbiota-The University of Texas Health Science Center, Houston-Clostridioides difficile infectionfecal microbiota transplant
Beyond the preview
Go deeper on fecal microbiota, live.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fecal microbiota, live.